–
Статьи в журналах
-
- 2024 Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
- Sangro B., Chan S.L., Kelley R.K., Lau G., Kudo M., Sukeepaisarnjaroen W., Yarchoan M., De Toni E.N., Furuse J., Kang Y.K., Galle P.R., Rimassa L., Heurgué A., Tam V.C., Van Dao T., Thungappa S.C., Breder V., Ostapenko Y., Reig M., Makowsky M., Paskow M.J., Gupta C., Kurland J.F., Negro A., Abou-Alfa G.K.
- в журнале Annals of Oncology, издательство Oxford University Press (United Kingdom), том 35, № 5, с. 448-457 DOI
-
- 2022 Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
- Abou-Alfa Ghassan K., Lau George, Kudo Masatoshi, Chan Stephen L., Kelley Robin Kate, Furuse Junji, Sukeepaisarnjaroen Wattana, Kang Yoon-Koo, Van Dao Tu, De Toni Enrico N., Rimassa Lorenza, Breder Valeriy, Vasilyev Alexander, Heurgué Alexandra, Tam Vincent C., Mody Kabir, Thungappa Satheesh Chiradoni, Ostapenko Yuriy, Yau Thomas, Azevedo Sergio, Varela María, Cheng Ann-Lii, Qin Shukui, Galle Peter R., Ali Sajid, Marcovitz Michelle, Makowsky Mallory, He Philip, Kurland John F., Negro Alejandra, Sangro Bruno
- в журнале NEJM Evidence, издательство NEJM Group (USA), том 1, № 8 DOI